key: cord-1044879-7tvbwnda
authors: Ku, Min-Wen; Bourgine, Maryline; Authié, Pierre; Lopez, Jodie; Nemirov, Kirill; Moncoq, Fanny; Noirat, Amandine; Vesin, Benjamin; Nevo, Fabien; Blanc, Catherine; Souque, Philippe; Tabbal, Houda; Simon, Emeline; Hardy, David; Le Dudal, Marine; Guinet, Françoise; Fiette, Laurence; Mouquet, Hugo; Anna, François; Martin, Annette; Escriou, Nicolas; Majlessi, Laleh; Charneau, Pierre
title: Intranasal Vaccination with a Lentiviral Vector Protects against SARS-CoV-2 in Preclinical Animal Models
date: 2020-12-16
journal: Cell Host Microbe
DOI: 10.1016/j.chom.2020.12.010
sha: 65d4e7bd030aac99ddb01a451c30639ced371244
doc_id: 1044879
cord_uid: 7tvbwnda

To develop a vaccine candidate against COVID-19, we generated a Lentiviral Vector (LV), eliciting neutralizing antibodies against the Spike glycoprotein of SARS-CoV-2. Systemic vaccination by this vector in mice, in which the expression of the SARS-CoV-2 receptor hACE2 has been induced by transduction of respiratory tract cells by an adenoviral vector, confers only partial protection, despite high levels of serum neutralizing activity. However, eliciting an immune response in the respiratory tract through an intranasal boost results in > 3 log10 decrease in the lung viral loads and reduces local inflammation. Moreover, both integrative and non-integrative LV platforms display strong vaccine efficacy and inhibit lung deleterious injury in golden hamsters, which are naturally permissive to SARS-CoV-2 replication and closely mirror human COVID-19 physiopathology. Our results provide evidence of marked prophylactic effects of the LV-based vaccination against SARS-CoV-2 and designate intranasal immunization as a powerful approach against COVID-19.

To develop a vaccine candidate able to induce NAbs against S CoV-2 , we generated LV harboring, 102 under the transcriptional control of the cytomegalovirus (CMV) immediate-early promoter, codon-103 optimized sequences encoding for: (i) S1 alone (LV::S1), (ii) S1-S2 ectodomain, without the 104 transmembrane and C-terminal short internal tail (LV::S1-S2), and (iii) full-length, membrane 105 anchored form of S (LV::S FL ), which all harbor the RBD ( Figure 1A , Figure S1 ), albeit with potential 106 conformational heterogeneities (Yuan et al., 2020) . To evaluate the humoral responses induced by 107 these vectors, C57BL/6 mice (n = 4/group) were immunized by a single intraperitoneal (i.p.) 108 injection of 1 × 10 7 Transduction Units (TU) of either LV, or an LV encoding GFP as negative 109 control. Anti-S CoV-2 Ab responses were investigated in the sera at weeks 1, 2, 3, 4 and 6 post 110 immunization ( Figure 1B ). In LV::S FL or LV::S1-S2-immunized mice, anti-S CoV-2 immunoglobulin G 111 (IgG) were detectable as early as 1 week post immunization and increased progressively until week 6 112 post immunization, achieving mean titer (1/dilution) ± SEM of (4.5 ± 2.9) × 10 6 or (1.5 ± 1) × 10 6 , 113 respectively. In comparison, anti-S CoV-2 IgG titers were 2 orders of magnitude lower, i.e., (7.1 ± 6.1) 114 ×10 4 , in their LV::S1-immunized counterparts. Sera were then evaluated for their capacity to 115 neutralize SARS-CoV-2, using a reliable neutralization assay based on NAb-mediated inhibition of 116 hACE2 + cell invasion by non-replicative LV particle surrogates, pseudo-typed with S CoV-2 (Sterlin et 117 al., 2020) . Such S CoV-2 pseudo-typed LV particles, harbor a luciferase reporter gene, which allows 118 quantitation of the hACE2 + host cell invasion. In this assay, the luciferase activity is inversely 119

proportional to the neutralization efficiency of NAbs present in biological fluids. Fine comparison, by 120 50% Effective Concentrations (EC50) assays of the sera from the LV::S1-, LV::S1-S2-or LV::S FL -121 immunized mice clearly established that LV::S FL was the most potent vector at inducing anti-S CoV-2 122 NAbs ( Figure 1C ). Moreover, neutralization activities were correlated with anti-S CoV-2 IgG titers only 123 in the sera of LV::S FL -immunized mice ( Figure 1D ). These results suggest that the conformation of 124 relevant B-cell epitopes is likely to be preserved in S FL but not necessarily in S1 or S1-S2 125 polypeptides, which could be crucial for giving rise to NAbs. Comparison of the sera from the 126 LV::S FL -immunized mice and a cohort of mildly symptomatic infected individuals living in Crépy-127 en-Valois, one of the first epidemic zones to appear in France, revealed similar mean neutralizing 128 activities ( Figure 1E ). These data predict a potentially protective humoral response induced by 129 Deconvolution of these positive pools allowed identification of S:256-275 135 (SGWTAGAAAYYVGYLQPRTF), S:536-550 (NKCVNFNFNGLTGTG) and S:576:590 136 (VRDPQTLEILDITPC) immunodominant epitopes, giving rise to > 2000 Spot Forming Unit (SFU) / 137 1 × 10 6 splenocytes ( Figure 2B ). These epitopes elicited CD8 + -but not CD4 + -T cells, as assessed 138 by intracellular cytokine staining ( Figure 2C ). The predominant CD8 + phenotype of these T cells is in 139 accordance with the favored orientation of LV-encoded antigens to the MHC-I presentation pathway 140 (Hu et al., 2011) . We also identified S:441-455 (LDSKVGGNYNYLYRL), S:671-685 141 (CASYQTQTNSPRRAR) and S:991-1005 (VQIDRLITGRLQSLQ) subdominant epitopes, which 142 gave rise to < 2000 SFU / 1 × 10 6 splenocytes in ELISPOT assay ( Figure 2B) . 143

Establishment of a murine model expressing hACE2 in the respiratory tracts 144

As S CoV-2 does not interact well with murine ACE2, wild-type laboratory mice are not permissive 145 to replication of SARS-CoV-2 clinical isolates. Therefore, we sought to develop a murine model in 146 which human ACE2 (hACE2) expression was induced in the respiratory tracts and pulmonary 147 mucosa to evaluate the LV::S FL vaccine efficacy. This method has been successfully used to establish 148 the expression of human DPP4 for the study of mouse infection with MERS-CoV (Zhao et al., 2014) 149 and also for hACE2 during the preparation of this manuscript . We generated an 150

Ad5 vector to deliver the gene encoding for hACE2 under the transcriptional control of the CMV 151 promoter (Ad5::hACE2). We first checked in vitro the potential of the Ad5::hACE2 vector to 152 transduce HEK293T cells by Reverse Transcriptase (RT)-PCR ( Figure 3A ). To achieve in vivo 153 transduction of respiratory tract cells, we instilled intranasally (i.n.) 2.5 × 10 9 Infectious Genome 154 Units (IGU) of Ad5::hACE2 into C57BL/6 mice. Four days later, the hACE2 protein expression was 155 detectable in the lung cell homogenate by Western Blot ( Figure 3B ). To get more insights into the in 156 vivo expression profile of a transgene administered under these conditions, we instilled i.n. the same 157 dose of an Ad5::GFP reporter vector into C57BL/6 mice. As evaluated by flow cytometry, 4 days 158 post instillation, the GFP reporter was expressed not only in the lung epithelial EpCam + cells, but 159 also in lung immune cells, as tracked by the CD45 pan-hematopoietic marker ( Figure 3C ), showing 160 that through this approach the transduction was efficiently achieved in epithelial cells, although not 161 restricted to these cells. 162

To evaluate the permissibility of such hACE2-transduced mice to SARS-CoV-2 infection, 4 days 163 after i.n. pretreatment with either Ad5::hACE2 or an empty Ad5 control vector, C57BL/6 mice were 164 inoculated i.n. with 1 × 10 5 TCID 50 (Median Tissue Culture Infectious Dose) of a SARS-CoV-2 165 clinical isolate (BetaCoV/France/IDF0372/2020) (Lescure et al., 2020) . The lung viral loads, 166 determined at 2 days post inoculation (dpi) by reverse transcription and quantitative real-time PCR 167 (qRT-PCR), were as high as (4.4 ± 1.8) × 10 9 copies of SARS-CoV-2 RNA in Ad5::hACE2-168 pretreated mice, compared to only (6.2 ± 0.5) × 10 5 copies in empty Ad5-pretreated mice, or (4.0 ± 169 2.9) × 10 5 copies in un-pretreated mice ( Figure 3D ). In the latter two control groups, these copy 170 numbers corresponded to the input viral RNA, as determined in Ad5::hACE2-pretreated mice, 171 inoculated with equivalent amounts of heat-killed viral particles ( Figure 3D ). Increase of viral load 172 from 10 6 copies to >10 9 copies/lungs shows the occurrence of active replication of SARS-CoV-2 in 173 vivo. At 4 dpi, the lung viral loads were maintained in Ad5::hACE2-pretreated mice (2.8 ± 1.3 × 10 9 174 copies), whereas a drop to (1.7 ± 2.3) × 10 4 or (3.9 ± 5.1) × 10 3 copies was observed in empty Ad5-175 pretreated or non-pretreated mice, respectively. In Ad5::hACE2-pretreated mice, the viral loads were 176 still detectable at 7 dpi ((1.33 ± 0.9) × 10 6 copies). 177

Ad5::hACE-2 i.n. instillation induced CD45 + cell recruitment to the lungs ( Figure 3E ). However, 178 no pro-inflammatory effect was seen with a lower dose of 4 x 10 8 IGU/mouse ( Figure 3E ), which still 179 conferred full permissibility to SARS-CoV-2 replication ( Figure 3F ), and this dose was therefore 180 chosen for the subsequent experiments described below. In this model of permissive mice, SARS-181

CoV-2 infection resulted in widespread infiltration of the lung interstitium by mononuclear 182 inflammatory cells, i.e., lymphocytes and macrophages, at 3 dpi ( Figure S2 ). However, in the 183 Ad5::hACE2-pre-treated and SARS-CoV-2-inoculated mice, we did not observe any weight loss or 184 clinical signs of disease over the period of 2 to 7 days after virus inoculation. 185

These results show that pretreatment of mice with appropriate doses of Ad5::hACE2 can render 186 mice permissive to SARS-CoV-2 replication without inducing Ad5-mediated inflammation, thus 187 providing a valuable model for vaccine or drug studies. 188

Intranasal boost with LV::S FL protects strongly against SARS-CoV-2 in mice 189

To investigate the prophylactic potential of LV::S FL against SARS-CoV-2, C57BL/6 mice (n = 4-190 5/group) were injected i.p. with a single dose of 1 × 10 7 TU of LV::S FL or a negative control LV 191 (sham). At week 7 post immunization, mice were pretreated with Ad5::hACE2, and 4 days later, 192 inoculated i.n. with 1 × 10 5 TCID 50 of SARS-CoV-2 ( Figure S3A ). At 3 dpi, the lung viral loads in 193 LV::S FL -vaccinated mice were reduced by ~ 6.5 folds, i.e., mean ± SD of (5.5 ± 3.8) × 10 8 CoV-2 RNA copies compared to (3.1 ± 1.9) × 10 9 or (4.3 ± 3.0) × 10 9 copies in the un-or sham-195 vaccinated mice, respectively ( Figure S3B ). Therefore, a single i.p. LV::S FL injection provided only 196 partial protection in the lung, despite intense serum NAb activity. 197

To further improve the prophylactic effect, we evaluated the prime-boost or prime-target 198 approaches. C57BL/6 mice (n = 4-5/group) were primed i.p. with 1 × 10 7 TU of LV::S FL or a control 199 LV at week 0, and then boosted at week 3 with: (i) 1 × 10 7 TU of the same LV via the i. 4B, left) than against the S1 or RBD fragments ( Figure S4A ). In contrast, mucosal targeting with 205 LV::S FL via i.n. did not lead to a statistically significant improvement of anti-S CoV-2 IgG titers at the 206 systemic level ( Figure 4B left, Figure S4A ). In terms of serum neutralization potential, even though a 207 trend to increase was observed after i.p. or i.n. boost, the differences did not reach statistical 208 significance ( Figure 4B right) . 209

All mice were then pretreated with Ad5::hACE2 and challenged i.n. with 0.3 × 10 5 TCID 50 of 210 SARS-CoV-2 at week 4 post prime. At 3 dpi, the lung viral loads were significantly lower in LV::S FL 211 i.p.-i.p. immunized mice, i.e., mean ± SD (2.3 ± 3.2) × 10 8 , than in sham-vaccinated mice (13.7 ± 212 7.5) × 10 8 copies of SARS-CoV-2 RNA, ( Figure 4C ) This viral load reduction was similar to that 213 obtained with a single LV::S FL administration ( Figure S3B ). Most importantly, after i.n. LV::S FL 214 target immunization, > 3 log10 decrease in viral loads was observed and 2 out of 5 mice harbored 215 undetectable lung viral loads as determined by qRT-PCR assay. We also determined the viral loads in 216 the lungs of these mice by Plaque Forming Unit (PFU) assay ( Figure S4C of an empty LV via i.p. and then i.n. routes. Strong and comparable anti-S CoV-2 IgG Abs were 262 detected by ELISA in the sera of hamsters from the three vaccinated groups, before and after the i.n. 263 boost ( Figure 6B ). Post boost/target serology detected neutralization activity in all groups, with the 264 highest EC50 average observed in "int LV::S FL i.p.-i.n. High" individuals. Such levels were 265 comparable to those detected in COVID-19 cases in humans ( Figure 6C ). All hamsters were 266 challenged i.n. with 0.3 × 10 5 TCID 50 of SARS-CoV-2 at week 5. Up to 16% weight loss was 267 progressively reached at 4 dpi in sham-vaccinated individuals, compared to a non-significant loss in 268 the LV::S FL -vaccinated groups ( Figure 6D ). As assessed by qRT-PCR, at 2 dpi, decreases of ~ 1.2-to-269 assay, at 2 and 4 dpi, we detected (6.56 ± 1.88) and (2.94 ± 3.16) × 10 6 PFU/lung of sham-vaccinated 274 controls. At 2 dpi, the decrease in the viral loads were largely statistically significant in all of the 275 LV::S FL -vaccinated hamsters and at 4 dpi, with the exception of one "NILV::S FL i.m.-i.n." hamster, 276 no vaccinated individuals possessed detectable infectious viral particles ( Figure S5A ). 277

As evaluated by qRT-PCR in the total lung homogenates of the protected "int LV::S FL i.p.-i.n. 278

Low", "int LV::S FL i.p.-i.n. High" and "NILV::S FL i.m.-i.n." groups, substantial decreases were 279 observed at 4 dpi in the expression of inflammatory IFN-γ and IL-6 cytokines, anti-inflammatory IL-280 10 cytokine, and CCL2, CCL3 and CXCL10 chemokines, compared to their unprotected sham-281 vaccinated counterparts ( Figure 6F) . The other inflammatory mediators tested were not significantly 282 modified ( Figure S5B ). 283

In sham-vaccinated and challenged hamsters, overall marked multifocal degenerative changes of 284 the bronchial/bronchiolar epithelium, moderate effacement of the epithelium, associated with mild to 285 moderate mixed inflammation in the airway lumen, and minimal multifocal interstitial mononuclear 286 cell inflammation were detected at both time-points ( Figure S6A ). At 4 dpi, effacement of the 287 respiratory epithelium and mixed inflammation in the alveoli were more severe; moderate fibrin 288 deposits were also noted. In vaccinated hamsters, regardless of the vaccine dose, lung lesions were 289 clearly of lower incidence and severity ( Figure S6B ). In these animals, only minimal degenerative of S CoV-2 protein (S FL , S1-S2 and S1) encoded by LV injected to mice. RBD, S1/S2 and S2' cleavage 450

Dynamic of anti-S CoV-2 Ab response following LV immunization. C57BL/6 mice (n = 4/group) were 452 injected i.p. with 1 × 10 7 TU of LV::GFP as a negative control, LV::S1, LV::S1-S2, or LV::S FL . Sera 453 were collected at 2, 3, 4 and 6 weeks post immunization. Anti-S CoV-2 IgG responses were evaluated 454 by ELISA and expressed as mean endpoint dilution titers. Ad5::hACE2, followed by i.n. inoculation of 1 × 10 5 TCID 50 of SARS-CoV-2 4 days later. Viral load 485 were determined at 3 dpi. See also Figure S2 . 486 HEK293T and Vero cells were cultured in DMEM media (Gibco Thermofisher) complemented 583 with 10% heat-inactivated serum (Corning), 100 U/ml penicillin and 100 µg/ml streptomycin (Gibco 584 Thermofisher) and were incubated at 37°C, 5% CO2. 585 586

Construction of transfer pFLAP plasmids coding for S FL , S1-S2, or S1 proteins 588 A codon-optimized full-length S (1-1273) sequence was amplified from pMK-RQ_S-2019-nCoV 589 and inserted between BamHI and XhoI sites of pFlap-ieCMV-WPREm. Sequences encoding for S1-590 S2 (1-1211) or S1 (1-681) were amplified by PCR from the pFlap-ieCMV-S FL -WPREm plasmid and 591 sub-cloned into pFlap-ieCMV-WPREm between the BamHI and XhoI restriction sites ( Figure S1 ). 592

Each of the PCR products were inserted between the native human ieCMV promoter and a mutated 593 Woodchuck Posttranscriptional Regulatory Element (mWPRE) sequence, in which the atg starting 594 codon was mutated to avoid transcription of the downstream truncated "X" protein of Woodchuck 595

Hepatitis Virus, in order to improve the vector safety. Plasmids were amplified in Escherichia coli 596 DH5a in Lysogeny Broth supplemented with 50 µg/ml of kanamycin and purified using the 597 NucleoBond Xtra Maxi EF Kit (Macherey Nagel) and resuspended in Tris-EDTA Endotoxin-Free 598 buffer overnight. Plasmid were quantified with a NanoDrop 2000c spectrophotometer (Thermo 599

Ficher, Illkirch, France), aliquoted and stored at -20°C. Plasmid DNA were verified by enzymatic 600 digestion and by sequencing the region proximal to the transgene insertion sites. 601 an 8xHis Tag were synthetized and cloned into pcDNA™3.1/Zeo (+) expression vector (Thermo 635 Fisher). Proteins were produced by transient co-transfection of exponentially growing Freestyle™ 636 293-F suspension cells (Thermo Fisher) using polyethylenimine (PEI)-precipitation method as 637 previously described (Lorin and Mouquet, 2015) . Recombinant S CoV-2 proteins were purified by 638 affinity chromatography using the Ni Sepharose® Excel Resin according to manufacturer's 639 instructions (Thermo Fisher). Protein purity was evaluated by in-gel protein silver-staining using 640

Pierce Silver Stain kit (Thermo Fisher) following SDS-PAGE in reducing and non-reducing 641 conditions using NuPAGE™ 3-8% Tris-Acetate gels (Life Technologies). Purified proteins were 642 dialyzed overnight against PBS using Slide-A-Lyzer® dialysis cassettes (10 kDa MW cut-off, 643

Thermo Fisher). Protein concentration was determined using the NanoDrop™ One instrument 644 (Thermo Fisher). 645

Ninety-six-well Nunc Polysorp plates (Nunc, Thermo Ficher) were coated overnight at 4 °C with 647 100 ng/well of purified S CoV-2 proteins in carbonate-bicarbonate buffer (pH 9.6). The next day, plates 648 were blocked with carbonate buffer containing 1% BSA for 2 h at 37°C. Wells were then washed 649 with PBS containing 0.05% Tween 20 (PBS-T), 1:100-diluted sera or 1:10-diluted lung homogenates 650 in PBS-T containing 1% BSA and four serial ten-to-ten dilutions were added and incubated during 2h 651 at 37°C. After PBS-T washings, plates were incubated with 1,000-fold diluted peroxydase-652 conjugated goat anti-mouse IgG (Jackson ImmunoResearch Europe Ltd, Cambridgeshire, United 653 Kingdom) for 1 h. Plates were revealed by adding 100 µl of 3,3',5,5'-tetramethylbenzidine 654 chromogenic substrate (Eurobio Scientific). Following a 30 min incubation, reaction was stopped by 655 adding 100 µl of 2N H2SO4 and optical densities were measured at 450nm/620nm on a PR3100 656 reader. 657

Serial dilutions of heat inactivated sera or clarified lung homogenates were assessed for NAbs via 659 an inhibition assay which uses HEK293T cells transduced to stably express human ACE2 and non-660 replicative S CoV-2 pseudo-typed LV particles which harbor the reporter luciferase firefly gene, 661 allowing quantitation of the host cell invasion by mimicking fusion step of native SARS-CoV-2 virus 662 (Sterlin et al., 2020) . First, 1.5 × 10 2 TU of S CoV-2 pseudo-typed LV were pre-incubated, during 30 663 min at room temperature, in U-bottom plates, with serial dilutions of each serum in a final volume of 664 50µl in DMEM-glutamax, completed with 10% heat-inactivated FCS and 100 U/ml penicillin and 665 100 µg/ml streptomycin. The samples were then transferred into clear-flat-bottom 96-well-black-666 plates (Corning), and each well received 2 × 10 4 hACE2 + HEK293-T cells, counted in a 667

NucleoCounter NC.200 system (Chemometec, Denmark) contained in 50 µl. After 2 days incubation 668 at 37°C 5% CO 2 , the transduction efficiency of hACE2 + HEK293-T cells by pseudo-typed LV L18 (RLP18) was used as an endogenous reference control to normalize differences in the amount of 773 input nucleic acid. The average C T values were calculated from the technical replicates for relative 774 quantification of target cytokines/chemokines. The differences in the C T cytokines/chemokines 775 amplicons and the C T of the endogenous reference control, termed ∆C T, were calculated to normalize 776 for differences in the quantity of nucleic acid. The ∆C T of the experimental condition compared 777 relatively to the PBS-immunized individuals using the comparative ∆∆C T method. The fold change in 778 gene expression was further calculated using 2 −∆∆C T . 779

Samples from the lung were fixed in formalin for at least 7 days and routinely embedded in 781 paraffin. Five µm thick paraffin sections were stained with Hematoxylin Eosin & Saffron (HE&S) or 782 HE. Microscopic changes were qualitatively described and when applicable scored semi-783 quantitatively, by histopathologists blinded to the conditions, using: (i) distribution qualifiers (i.e., 784 focal, multifocal, locally extensive or diffuse), and (ii) a five-scale severity grade, i.e., 1: minimal, 2: 785 mild, 3: moderate, 4: marked and 5: severe. 786

Statistical parameters are presented as means ± SEM or ± SD and the exact number (n) of mice 788 per group are annotated in the corresponding figure legend and in the text. Statistical analysis of 789 virological and immunological data was performed using GraphPad Prism v9.0.0 (GraphPad 790 Software, CA, USA). Differences between two groups were evaluated by using unpaired two-tailed 791 nonparametric Mann-Whitney U test. For statistical analysis of multiple groups, the two-way 792 ANOVA followed by Sidak's multiple comparisons test was applied ( * p < 0.05; * * p < 0.01; * * * p < 793 0.001; * * * * p < 0.0001; ns, not statistically significant). 794 795 J o u r n a l P r e -p r o o f Highlights A lentiviral vector encoding for Spike shows preclinical efficacy as a COVID-19 vaccine.

Targeting the immune response to the upper respiratory tract provides critical protection.

Intranasal vaccination induces protective mucosal immunity against SARS-CoV-2 in rodents.

Lung anti-Spike IgA responses correlate with protection and reduced inflammation.

Ku and colleagues present a lentiviral vaccination vector that encodes a full-length, membrane anchored form of SARS-CoV-2 Spike glycoprotein that induces neutralizing antibodies and T-cell responses. An intranasal boost strategy triggers a localized immune response in the upper respiratory tract that provides disease protection in mouse and hamster COVID-19 models. 

Expression of hACE2 in the lungs of Ad5::hACE2-transduced mice was assessed by Western 705

One million cells from lung cell suspension were resolved on 4 -12 % NuPAGE Bis-Tris 706 protein gels (Thermo Fisher), then transferred onto a nitrocellulose membrane

Following three wash intervals of 10 minutes with PBS-T, the membrane was incubated for 1 hour at 710 room temperature with HRP-conjugated anti-goat secondary Ab and HRP-conjugated anti-β-actin 711 (ab197277, Abcam). The membrane was washed with PBS-T thrice before visualization with 712 enhanced chemiluminescence via the super signal west femto maximum sensitivity substrate

Determination of SARS-CoV-2 viral loads in the lungs

Half of each lung lobes were removed aseptically and frozen at -80°C. Organs were thawed and 717 homogenized for 20 s at 4.0 m/s, using lysing matrix M (MP Biomedical) in 500 µl of ice-cold PBS

The homogenization was performed in an MP Biomedical Fastprep 24 Tissue Homogenizer. The 719 homogenates were centrifuged 10 min at 2000g for further RNA extraction from the supernatants

Particulate viral RNA was extracted from 70 µl of such supernatants using QIAamp Viral RNA Mini 721

using SuperScript TM III Platinum One-Step Quantitative RT-PCR System (Invitrogen) and 724 primers and probe (Eurofins) targeting S CoV-2 gene as listed in Table S1

then purified by phenol/chloroform extractions and 727 two successive precipitations with isopropanol and ethanol. RNA concentration was determined by 728 optical density measurement, then RNA was diluted to 10 9 genome equivalents/µL in RNAse-free 729 water containing 100µg/mL tRNA carrier, and stored in single-use aliquots at -80°C. Serial dilutions 730 of this in vitro transcribed RNA were prepared in RNAse-free water containing 10µg/ml tRNA 731 carrier and used to establish a standard curve in each assay

reverse transcription at 55°C for 10 min, (ii) enzyme inactivation at 95°C for 3 min, and (iii)

cycles of denaturation/amplification at 95°C for 15 s, 58°C for 30 s. Products were analyzed on an 734

ABI 7500 Fast real-time PCR system (Applied Biosystems). PFU assay was performed as recently 735 described

Cytometric analysis of lung cells

Lungs from individual mice were treated with 400 U/ml type IV collagenase and DNase I (Roche)

for a 30-minute incubation at 37°C and homogenized by use of GentleMacs

Cells were filtered through 100 µm-pore filters and centrifuged at 1200 rpm during 8 minutes

Cells were then treated with Red Blood Cell Lysing Buffer (Sigma) and washed twice in PBS. Cells 741 were stained as follows. (i) To detect DC, monocytes, alveolar and interstitial macrophages

FcγII/III receptor blocking anti-CD16/CD32 (BD Biosciences)

CD45 (BD Biosciences), PE-anti-CD11b (eBioscience), PE-Cy7-antiCD11c (eBioscience), BV450-744 anti-CD64 (BD Biosciences), FITC-anti-CD24 (BD Biosciences)

PerCP-Cy5.5-anti-Ly6C (eBioscience) and APC anti-Ly-6G

Miltenyi) mAbs, (ii) to detect neutrophils or eosinophils: Near IR DL (Invitrogen), FcγII/III receptor 747 blocking anti-CD16/CD32 (BD Biosciences), PerCP-Vio700-anti-CD45 (Miltenyi

CD11b (BD Biosciences), PE-Cy7-anti-CD11c (eBioscience), FITC-anti-CD24 (BD Biosciences

ii) to detect mast cells, basophils, NK: Near IR LD (Invitrogen

PE-anti-CD11b (eBioscience), eF450-anti-CD11c (eBioscience)

CD117 (BD Biosciences), APC-anti-FcεR1 (BioLegend), AF700-anti-NKp46 (BD Biosciences

without FcγII/III receptor blocking anti-CD16/CD32. Cells were 754 incubated with appropriate mixtures for 25 minutes at 4°C, washed twice in PBS containing 3% FCS 755 and then fixed with Paraformaldehyde 4% by an overnight incubation at 4°C. The cells were acquired 756 in an Attune NxT cytometer system (Invitrogen) and data were analyzed by FlowJo software 757

Detection of inflammatory cytokines and chemokines in the lungs of the mice and 759

Lung samples from mice or hamsters were added to lysing matrix D (MP Biomedical) containing

1 mL of TRIzol reagent and homogenized at 30 s at 6.0 m/s twice using

Total RNA was extracted using TRIzol reagent (ThermoFisher) according to 763 the manufacturer's procedure. cDNA was synthesized from 4 µg of RNA in the presence of 2.5 µM 764 of oligo(dT) 18 primers, 0.5 mM of deoxyribonucleotides

20 µl reaction. The real-time PCR was performed on

4 µl of cDNA diluted 1:15 in DEPC-water and 0.5 µl of each forward and reverse 769 primers at a final concentration of 0.5 µM (Table S2). The following thermal profile was used: a 770 single cycle of polymerase activation for 3 min at 95°C

sec at 95°C and 30 sec 60°C (annealing-extension step). Mice β-globin or hamster ribosomal protein 772

SARS-CoV-2 Vaccines: Status Report

Lentiviral vector-based prime/boost vaccination against AIDS: pilot study shows 799 protection against Simian immunodeficiency virus SIVmac251 challenge in macaques

Activation of the SARS coronavirus spike 802 protein via sequential proteolytic cleavage at two distinct sites

Nasal 805 route favors the induction of CD4+ T cell responses in the liver of HBV-carrier mice immunized with 806 a recombinant hepatitis B surface-and core-based therapeutic vaccine

Evaluation of a self-inactivating lentiviral vector expressing simian 809 immunodeficiency virus gag for induction of specific immune responses in vitro and in vivo

Growth, detection, 812 quatification, and inactivation od SARS-CoV-2

SARS-CoV-2 infection protects against rechallenge 815 in rhesus macaques

Diagnostic detection of 2019-nCoV 817 by real-time RT-PCR

Persistence of Integrase-Deficient Lentiviral Vectors 820 Correlates with the Induction of STING-Independent CD8(+) T Cell Responses

A nonintegrative lentiviral vector-based 824 vaccine provides long-term sterile protection against malaria

The 826 spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in 827 CoV of the same clade

HIV-derived 829 vectors for therapy and vaccination against HIV. Vaccine

Efficient transduction of dendritic cells and 831 induction of a T-cell response by third-generation lentivectors

Use of a lentiviral flap vector for induction of CTL 834 immunity against melanoma. Perspectives for immunotherapy

A rapid Q-PCR titration protocol for adenovirus and helper-836 dependent adenovirus vectors that produces biologically relevant results

Integrase Defective Lentiviral Vector as a Vaccine 839 Platform for Delivering Influenza Antigens

Rapid development of an inactivated vaccine candidate for SARS-CoV-2

A comparison of four serological assays for 845 detecting anti-SARS-CoV-2 antibodies in human serum samples from different populations

The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) 849 outbreak -an update on the status

A SARS-CoV-2 Infection Model in Mice 852 Demonstrates Protection by Neutralizing Antibodies

Immunization with lentiviral 854 vector-transduced dendritic cells induces strong and long-lasting T cell responses and therapeutic 855 immunity

DNA Vaccines-How Far From Clinical Use?

Immunization delivered by lentiviral vectors for cancer and 858 infectious diseases

A 860 single immunization with a minute dose of a lentiviral vector-based vaccine is highly effective at 861 eliciting protective humoral immunity against West Nile virus

A Single Dose of NILV-Based Vaccine Provides Rapid and Durable Protection against 864

Zika Virus. Mol Ther

High-Quality Memory T Cells by Programmed Antigen Expression in Dendritic Cells 867 Induced by Lentiviral Vector

The SARS-CoV Fusion

Peptide Forms an Extended Bipartite Fusion Platform that Perturbs Membrane Order in a Calcium-870 Dependent Manner

Clinical and virological data of 873 the first cases of COVID-19 in Europe: a case series

An Optimized Poly-antigenic Lentiviral Vector Induces 876

Protective CD4+ T-Cell Immunity and Predicts a Booster Vaccine against Mycobacterium 877 tuberculosis

Efficient generation of human IgA monoclonal antibodies

Animal models for COVID 881 19

Single-dose treatment with a humanized neutralizing antibody affords full protection of a 884 human transgenic mouse model from lethal Middle East respiratory syndrome (MERS)-coronavirus 885 infection

Immunizing patients with metastatic 888 melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens

CD4+ T Cells Recognizing PE/PPE Antigens Directly or

via Cross Reactivity Are Protective against Pulmonary Mycobacterium tuberculosis Infection

The immunogenicity of 895 adenovirus vectors limits the multispecificity of CD8 T-cell responses to vector-encoded transgenic 896 antigens

Pathogenesis and transmission of SARS-CoV-2 in 899 golden hamsters

IgA dominates the early neutralizing antibody response to 903 SARS-CoV-2

Generation of a Broadly Useful Model for COVID-19 Pathogenesis, Vaccination, and 906 Treatment

Immunology of COVID-19: Current State of the Science

Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry

A Unique Protease 916

Cleavage Site Predicted in the Spike Protein of the Novel Pneumonia Coronavirus

Potentially Related to Viral Transmissibility

DNA vaccine protection against SARS-CoV-2 in 921 rhesus macaques

HIV-1 925 genome nuclear import is mediated by a central DNA flap

Rapid generation of a mouse model for Middle East 928 respiratory syndrome

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 931 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised

Non-replicative LV were produced in Human Embryonic Kidney (HEK)-293T cells, as previously 603 detailed (Zennou et al., 2000) . Briefly, lentiviral particles were produced by transient calcium 604 phosphate co-transfection of HEK293T cells with the vector plasmid pTRIP/sE, a VSV-G Indiana 605 envelope plasmid and an encapsidation plasmid (p8.74 or pD64V for the production of integration-606 proficient or integration-deficient vectors respectively). Supernatants were harvested at 48h post 607 transfection, clarified by 6-minute centrifugation at 2500 rpm at 4°C. LV were aliquoted and stored 608 at -80°C. Vector titers were determined by transducing 293T cells treated with aphidicolin. The titer, 609proportional to the efficacy of nuclear gene transfer, is determined as Transduction Unit (TU)/ml by 610 qPCR on total lysates at day 3 post transduction, by use of forward 5'-TGG AGG AGG AGA TAT 611 GAG GG-3' and reverse 5'-CTG CTG CAC TAT ACC AGA CA-3' primers, specific to pFLAP 612 plasmid and forward 5'-TCT CCT CTG ACT TCA ACA GC-3' and reverse 5'-CCC TGC ACT TTT 613 TAA GAG CC-3' primers specific to the host housekeeping gene gadph as previously described 614 (Iglesias et al., 2006) . 615

Hamsters or Ad5::hACE2-pretreated mice were anesthetized by i.p. injection of mixture Ketamine 617 and Xylazine, transferred into a biosafety cabinet 3 where they were inoculated i.n. with 618BetaCoV/France/IDF0372/2020 SARS-CoV-2 clinical isolate (Lescure et al., 2020), amplified in 619 VeroE6 cells. The strain BetaCoV/France/IDF0372/2020 was supplied by the National Reference 620Centre for Respiratory Viruses hosted by Institut Pasteur (Paris, France) and headed by Pr. Sylvie van 621 der Werf. The human sample from which strain BetaCoV/France/IDF0372/2020 was isolated has 622 been provided by Dr. X. Lescure and Pr. Y. Yazdanpanah from the Bichat Hospital, Paris, France. 623During the progression of our experiments, we observed that reducing the input SARS-CoV-2 dose 624 from 1 × 10 5 to 0.3 × 10 5 TCID 50 /individual did not impact the plateau of the lung viral loads 625 reached at 2-4 dpi. Therefore, in many studies we used the lower dose to mimic better the natural 626 infectious dose. The viral inoculum was contained in 20 µl for mice and in 50 µl for hamsters. 627Animals were then housed in an isolator in BioSafety Level 3 animal facilities of Institut Pasteur. The 628 organs and fluids recovered from the animals infected with live SARS-CoV-2 were manipulated 629 following the approved standard operating procedures of these facilities. 630

Codon-optimized nucleotide fragments encoding a stabilized foldon-trimerized version of the 632 SARS-CoV-2 S ectodomain (a.a. 1 to 1208), the S1 monomer (a.a. 16 to 681) and the RBD 633 subdomain (amino acid 331 to 519) both preceded by a murine IgK leader peptide and followed by 634 particles was determined by measuring the luciferase activity, using a Luciferase Assay System 670 (Promega) on an EnSpire plate reader (PerkinElmer), as detailed elsewhere (Sterlin et al., 2020) . 671Results are expressed as percentages of inhibition of luciferase activity compared to the maximum of 672 luciferase activity in the absence of NAbs. Sera were heat-inactivated by 30 min incubation at 56°C 673 and were manipulated in BSL2 conditions. 674

In order to map the immuno-dominant epitopes of S CoV-2 , peptides spanning the whole S FL 676 (Mimotopes, Australia) were pooled by 16, each containing 15 a.a. residues overlapping by 10 a.a.  677 Peptides were dissolved in DMSO at a concentration of 2 mg/ml and diluted before use at 1 µg/ml for 678 ELISPOT or 2-5 µg/ml for ICS (Intracellular Cytokine Staining) in RΡΜΙ−1640 medium 679 supplemented with 10% FCS, 100 U/ml penicillin, 100 µg/ml streptomycin, 1 x 10 -4 M non-essential 680 amino-acids, 1% vol/vol HEPES, 1 x 10 -3 M sodium pyruvate and 5 × 10 -5 M of β-mercapto-ethanol. Adenoviral Promoterless Gateway Expression Kit, Thermo Fisher). The Ad5 particles were purified 700 using Adeno-X rapid Maxi purification kit and concentrated with the Amicon Ultra-4 10k centrifugal 701 filter unit. Vectors were resuspended and stored à -80°C in PIPES buffer pH 7.5, supplemented with 702 2.5% glucose. Ad5 were titrated using a qPCR protocol, as described (Gallaher and Berk, 2013) . 703